Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Stemcell United Ltd. ( (AU:BP8) ) is now available.
BPH Global Ltd’s Indonesian subsidiary, PT BPH Global Indonesia, has signed a binding Memorandum of Understanding with Indonesia’s National Research and Innovation Agency (BRIN) under the government’s “BRIN Goes to Industries” initiative, a program aimed at accelerating the commercialisation of national research and strengthening strategic industrial capabilities. The agreement, which runs for an initial three-year term, establishes a framework for accessing and potentially licensing BRIN’s existing intellectual property in fucoidan extraction technology and undertaking co-development R&D, enabling BPH Global to advance into higher-margin, fucoidan-based anti-ageing and personal-care products and deepening its integration into Indonesia’s innovation ecosystem alongside a select group of industrial partners.
The most recent analyst rating on (AU:BP8) stock is a Sell with a A$0.06 price target. To see the full list of analyst forecasts on Stemcell United Ltd. stock, see the AU:BP8 Stock Forecast page.
More about Stemcell United Ltd.
BPH Global Ltd (ASX: BP8) is a leading commercial seaweed supply and export company operating through its Indonesian subsidiary, PT BPH Global Indonesia, with a strategic focus on value-added seaweed derivatives. The company is targeting high-growth applications such as fucoidan-based anti-ageing and personal-care products, positioning itself within the broader marine bioactives and cosmetics supply chain in Indonesia and global markets.
Current Market Cap: A$3.71M
Learn more about BP8 stock on TipRanks’ Stock Analysis page.